AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03495648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group led by a community organizer
Description: Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
Study NCT00617461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg/day
Description: 1200mg/day gabapentin enacarbil
Study NCT00617461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 3600mg/day
Description: 3600mg/day gabapentin enacarbil
Study NCT00944970 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: binodenoson
Description: 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
Study NCT00944970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Study NCT00944970 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: adenosine
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Study NCT02102165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metastatic lesion biopsy
Description: a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
Study NCT03879213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active breakfast
Description: freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
Study NCT03879213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control breakfast
Description: Control drink + buttermilk biscuit sandwich
Study NCT00910182 — intervention group
Intervention type: PROCEDURE
Intervention: splenorrhaphy
Description: surgical treatment of splenic injuries after blunt abdominal trauma.
Study NCT04428671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study NCT04428671 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study NCT04428671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study NCT04184037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation delivered via a mobile app
Description: This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided.
Study NCT04184037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation delivered via a mobile app
Description: This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided.
Study NCT02686216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 THK-5351
Description: Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
Study NCT02901899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study NCT02901899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02901899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04638881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo. Bolus and infusion administered similarly under general anesthesia.
Study NCT04531254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearing a face mask at all times
Description: Children in this group will be asked to wear a face mask in the classroom and common areas during the simulation
Study NCT06209398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )
Description: Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.
Study NCT06209398 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )
Description: Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.
Study NCT06209398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B Vaccine
Description: Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.
Study NCT06209398 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B Vaccine
Description: Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.
Study NCT06209398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A meningococcal polysaccharide vaccine
Description: This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
Study NCT06209398 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A meningococcal polysaccharide vaccine
Description: This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
Study NCT02133794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Study NCT00567489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physioneal
Description: Physioneal 40 or Physioneal 35
Study NCT00567489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dianeal
Description: Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
Study NCT00567489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extraneal
Description: 7.5% Icodextrin
Study NCT04252469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral care
Description: oral care using 20mL of 0.12% CHX and gargling with 30 seconds.
Study NCT01085344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)
Description: escalating dose prophylaxis
Study NCT01085344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)
Description: escalating dose
Study NCT01576978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hatha yoga
Description: The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
Study NCT01550211 — intervention group
Intervention type: DEVICE
Intervention: Magnetoencephalograph (MEG)
Description: Conducting a brain scan during a series of perceptual and linguistic tasks
Study NCT01637038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
Study NCT00721643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: angel's plant (Angelica keiskei)
Description: Healthy control, one time dose of 5g dry power of Angelica keiskei
Study NCT00721643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Angel's plant (Angelica keiskei)
Description: Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
Study NCT03037879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPT
Description: Participants in the SPT group will receive 10 training sessions over 5 weeks.
Study NCT03037879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPT Control
Description: Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
Study NCT03037879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mSMT
Description: Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
Study NCT03037879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mSMT Control
Description: Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
Study NCT02388074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPath®
Description: CyPath® diagnostic assay for the early detection of lung cancer using sputum
Study NCT01483157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vascular occlusion with exercise trainig
Description: twelve weeks of resistance training with vascular occlusion twice a week
Study NCT01483157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity resistance training
Description: twelve weeks of resistance training twice a week
Study NCT02964715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 25 mg daily for 6 months
Study NCT03176043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV Fluid Administration
Description: Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
Study NCT03176043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV Fluid Administration
Description: Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
Study NCT01947595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intensified lifestyle intervention
Description: * physical activity 6 hours per week, 50% guided activity~  * recorded by an accelerometer (Aipermotion 440)~* 16 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)
Study NCT01947595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: normal lifestyle intervention
Description: * physical activity 3 hours per week~  * recorded by an accelerometer (Aipermotion 440)~* 8 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)
Study NCT01947595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single lifestyle advice
Description: - Single Health care advice and lifestyle advice (30 minutes) at the beginning~* recommend the individual target weight (5% less, if BMI 25> kg/m²)
Study NCT03857841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UNEX-42
Description: UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
Study NCT03857841 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: Phosphate-buffered saline
Study NCT04496843 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HWA09 Measurement
Description: Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
Study NCT04216979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy entry policy
Description: Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site.
Study NCT03792321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone Undecanoate
Description: 1000 mg i.m. every 10 weeks
Study NCT03792321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: 1000 mg i.m. every 10 weeks
Study NCT03792321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00567489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutrineal
Description: Amino Acids 1.1%
Study NCT00474929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
Study NCT00474929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
Study NCT00710112 — intervention group
Intervention type: GENETIC
Intervention: gene variations
Description: comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
Study NCT01996072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17
Study NCT00010439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
Study NCT00518128 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical OSA treatment
Description: uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
Study NCT00518128 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure Therapy
Description: Continuous positive airway pressure for treatment of obstructive sleep apnea
Study NCT00947037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-CD/LD
Study NCT00871403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib and pemetrexed
Description: oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily
Study NCT00871403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed and cisplatin
Description: pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks
Study NCT01995019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: 1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
Study NCT01995019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline
Description: 1 ml intra-articular placebo
Study NCT03389841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education of the caregiver about early symptoms and signs of heart failure
Study NCT02840175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks
Study NCT00884858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
Study NCT03431090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® TCRαβ/CD19 Combined Depletion System
Description: The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
Study NCT01982214 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sedentary
Description: No intervention
Study NCT01982214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
Study NCT01987596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
Study NCT02840175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks